Bone marrow ring sideroblasts in hematological diseases: an analysis of consecutive 1300 samples in a single institution

Int J Hematol. 2022 Apr;115(4):508-514. doi: 10.1007/s12185-021-03278-5. Epub 2022 Jan 22.

Abstract

The incidence of MDS-RS in Japan has been recognized as about 5% which is lower than that in European countries. Insufficient use of iron staining tests in Japan has been noted as one conceivable factor contributing to this apparently lower prevalence. To investigate this issue, we analyzed the proportion of ring sideroblasts (RS) in 1300 bone marrow samples from patients with hematological diseases at Kitasato University Hospital, including iron staining of all samples. Sixteen of 96 patients with MDS (16.7%) were diagnosed with MDS-RS, and this accounted for 26.2% of MDS without excess blasts. Some MDS-EB (22.9%) and AML-MRC (13.8%) patients also had ≥ 15% RS. In contrast, RS were rarely found in myeloid neoplasms without dysplasia and non-myeloid diseases: only 1 in 46 (2.2%) patients with AML without dysplasia, 2 in 93 (2.2%) with MPN, and 8 in 984 (0.8%) with non-myeloid diseases had ≥ 5% RS. These results indicate that prevalence of MDS-RS in Japan may be higher than conventionally recognized and that RS are principally restricted to myelodysplastic disorders. Further multicenter studies using consecutive bone marrow samples with iron staining tests will be required to confirm our findings.

Keywords: Iron staining test; MDS-RS; Myelodysplastic syndrome (MDS); Ring sideroblast (RS).

MeSH terms

  • Anemia, Sideroblastic* / diagnosis
  • Bone Marrow
  • Humans
  • Mutation
  • Myeloproliferative Disorders* / complications
  • Thrombocytosis*